Global Whole Genome and Exome Sequencing Market – Industry Trends and Forecast to 2030

Whole Genome and Exome Sequencing Market Analysis and Size

The key factors driving the global whole exome sequencing market are increasing applications in clinical diagnosis and the growing demand for diagnosing rare diseases, increasing R&D in genomics and next-generation sequencing, and rising demand for personalized medicine. For instance, an article published in the British Medical Journal in March 2022 reported that whole exome sequencing is available for highly selected patients for the routine diagnosis of rare childhood genetic diseases. The article also said that next-generation sequencing allows hundreds or thousands of genes to be sequenced quickly at a much lower cost. Due to the benefits of exome sequencing, the studied market is expected to grow over the forecast period.

Moreover, the growing adoption of personalized medicine is further estimated to provide potential opportunities for the growth of the whole genome and exome sequencing market in the forecast period.

Data Bridge Market Research analyses that the whole genome and exome sequencing market, which was USD 1,099.22 million in 2022, is likely to reach USD 4,719.86 million by 2030 and is expected to undergo a CAGR of 21.20% during the forecast period. This indicates that the market value. “Hospitals and Clinics” dominate the end-user segment of the whole genome and exome sequencing market due to the growing demand for products. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

The whole genome sequencing helps to provide rich information regarding single nucleotide, structural, or copy number variants, while exome sequencing often makes more sense when time or resources are limited. Exome sequencing is also known as whole exome sequencing (WES), and is a genomic procedure for sequencing all of the protein-coding regions of genes in a genome.

Global Whole Genome and Exome Sequencing Market Dynamics

Drivers

• Increasing prevalence of cancer

The most major element driving this market's growth is the rise in cancer incidence and expanding uses of next-generation sequencing in cancer research. This is attributable to the increased adoption of the next-generation sequencing for the treatment of cancer across the globe. People are now increasingly adopting these therapies for treatment as they are more effective and have low side effects, which is boosting the growth of the market significantly. Researchers are using these techniques to uncover genetic variations associated with diseases, personalized medicine, and other critical areas of study.

• Rise in the acceptance of next-generation sequencing methods

The total market is being driven by a growth in acceptability of next-generation sequencing approaches for the prediction, treatment, and monitoring of a variety of chronic diseases, such as cancer. Moreover, the integration of genomic sequencing into clinical and diagnostic settings has expanded the market. It is being used for the diagnosis of various genetic disorders and as a screening tool in prenatal and new-born care.

• Low cost and high speed of the technology

The cost of sequencing has significantly decreased over the years, making it more accessible to researchers, clinicians, and patients. This cost reduction has widened the market's reach and increased adoption. Thus, when compared to whole genome sequencing, whole exome sequencing has a lower cost which will further anticipated to propel the growth of the market.

Opportunity

• Technological advancement of therapies for the treatment

Continuous improvements in sequencing technologies and bioinformatics tools have enhanced the speed, accuracy, and efficiency of whole genome and exome sequencing. This, in turn, will extend profitable opportunities for the market players in the forecast period of 2023 to 2030 by enabling more comprehensive and cost-effective sequencing.

Moreover, it is anticipated that the market for whole genome and exome sequencing will exhibit lucrative growth with the ongoing developments in genomic research have expanded the applications of whole genome and exome sequencing.

Restraint/Challenge

• Dearth of skilled personnel

On the other hand, the dearth of skilled professionals and high reliability on grants is further projected to impede the growth of the whole genome and exome sequencing market in the targeted period. Moreover, the ethical and legal concerns regarding to whole exome sequencing might further challenge the growth of the whole genome and exome sequencing market in the forecast period of 2023-2030.

This whole genome and exome sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the whole genome and exome sequencing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2020, The "Genome India Project" was started by the Department of Biotechnology (DBT) (GIP). The goal of the initiative is to collect 10,000 genetic samples from Indian residents in order to create a reference genome. Precision health, rare genetic illnesses, the mutation spectrum of genetic and complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research are some of the areas of attention for this project

Global Whole Genome and Exome Sequencing Market Scope

The whole genome and exome sequencing market is segmented on the basis of technology, products and services, applications and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Others

Products and Services

• Products
• Systems
• Kits
• Services
• Sequencing Services
• Data Analysis Services
• Others

Applications                                                         

• Diagnostics
• Cancer
• Monogenic Disorders
• Diabetes
• Drug Discovery and Development
• Personalized Medicine
• Agriculture and Animal Research
• Others

End user

• Research Center
• Academic and Government Institutions
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Others

Global Whole Genome and Exome Sequencing Market Regional Analysis/Insights

The whole genome and exome sequencing market is analyzed, and market size insights and trends are provided by country, technology, products and services, applications, and end users, as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Brazil, Argentina, rest of South America, Germany, France, Italy, U.K., Belgium, Spain, Russia, Turkey, Netherlands, Switzerland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, U.A.E., Saudi Arabia, Egypt, South Africa, Israel, and rest of Middle East and Africa.

North America is expected to dominate the whole genome and exome sequencing market due to the rise in the incidence of genetic and chronic disorders, including cancer. Furthermore, the growing geriatric population and increasing demand for targeted and personalized medicine will further boost the growth of the whole genome and exome sequencing market in the region during the forecast period.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to the regular government funding. Moreover, the growing numbers of conferences regarding the whole exome sequencing technique is further anticipated to propel the growth of the whole genome and exome sequencing market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The whole genome and exome sequencing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for whole genome and exome sequencing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the whole genome and exome sequencing market. The data is available for historic period 2010-2020.

Competitive Landscape and Whole Genome and Exome Sequencing Market Share Analysis

The whole genome and exome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to whole genome and exome sequencing market.

Some of the major players operating in the whole genome and exome sequencing market are:

• DIGIRAD CORPORATION (U.S.)
• Neusoft Corporation (China)
• CANON MEDICAL SYSTEMS CORPORATION (Japan)
• SurgicEye GmbH (Germany)
• Mediso Ltd. (Hungary)
• CMR Naviscan. (U.S.)
• DDD-Diagnostic A/S (Denmark)
• Absolute Imaging Inc. (Canada)
• Bartec Technologies Ltd. (U.K.)
• BCL X-Ray Canada Inc. (Canada)
• TTG Imaging Solutions, LLC (U.S.)
• Mirion Technologies (Capintec), Inc. (U.S.)
• LANDAUER (U.S.)
• Ashby Gorman Baker Ltd. (Belgium)
• Lucerno Dynamics, LLC. (U.S.)
• Berthold Technologies GmbH & Co.KG (Germany)
• Incom, Inc. (U.S.)
• Siemens (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Spectrum Dynamics Medical (Switzerland)

SKU-68273